BACKGROUND: The prevalence of thrombophilic abnormalities in patients with cerebral vein thrombosis has been reported to be similar to that in patients with deep vein thrombosis of the lower limb. The role of gender-specific risk factors (pregnancy, oral contraceptives) is well established, whereas that of other acquired risk conditions is debated. MATERIALS AND METHODS: We screened 56 patients with cerebral vein thrombosis and 184 age- and sex-matched apparently healthy controls for prothrombin (factor II, FII) G20210A and factor V Leiden polymorphisms; protein S, protein C, and antithrombin deficiency; anticardiolipin antibodies; hyperhomocysteinaemia and other putative risk factors. RESULTS: The G20210A polymorphism was found in 29.1% of patients and in 5.7% of controls (odds ratio [OR] 7.1; P<0.0001; adjusted OR 12.67, P<0.0001). Frequencies of factor V Leiden and hyperhomocysteinaemia were not significantly different in patients and controls, nor were the other thrombophilic tests and some established cardiovascular risk factors, such as smoking, obesity or overweight and arterial hypertension. Conversely, 53.7% of the women who developed cerebral vein thrombosis did so while assuming oral contraceptives (OR 6.12; P<0.0001), with a further increase of risk in FII G20210A carriers (OR 48.533). Some associated diseases (onco-haematological disorders and infections) also had a significant role. Over a median 7-year follow-up, irrespective of the duration of antithrombotic treatment, 9/56 (16%) patients had further episodes of venous/arterial thrombosis. No significant risk factor for recurrent thrombosis was identified. DISCUSSION: In spite of the limitations of the sample size, our data confirm the role of FII G20210A mutation in this setting and its interactions with acquired risk factors such as oral contraceptives, also highlighting the risk of recurrent thrombosis in cerebral vein thrombosis patients.
BACKGROUND: The prevalence of thrombophilic abnormalities in patients with cerebral vein thrombosis has been reported to be similar to that in patients with deep vein thrombosis of the lower limb. The role of gender-specific risk factors (pregnancy, oral contraceptives) is well established, whereas that of other acquired risk conditions is debated. MATERIALS AND METHODS: We screened 56 patients with cerebral vein thrombosis and 184 age- and sex-matched apparently healthy controls for prothrombin (factor II, FII) G20210A and factor V Leiden polymorphisms; protein S, protein C, and antithrombin deficiency; anticardiolipin antibodies; hyperhomocysteinaemia and other putative risk factors. RESULTS: The G20210A polymorphism was found in 29.1% of patients and in 5.7% of controls (odds ratio [OR] 7.1; P<0.0001; adjusted OR 12.67, P<0.0001). Frequencies of factor V Leiden and hyperhomocysteinaemia were not significantly different in patients and controls, nor were the other thrombophilic tests and some established cardiovascular risk factors, such as smoking, obesity or overweight and arterial hypertension. Conversely, 53.7% of the women who developed cerebral vein thrombosis did so while assuming oral contraceptives (OR 6.12; P<0.0001), with a further increase of risk in FII G20210A carriers (OR 48.533). Some associated diseases (onco-haematological disorders and infections) also had a significant role. Over a median 7-year follow-up, irrespective of the duration of antithrombotic treatment, 9/56 (16%) patients had further episodes of venous/arterial thrombosis. No significant risk factor for recurrent thrombosis was identified. DISCUSSION: In spite of the limitations of the sample size, our data confirm the role of FII G20210A mutation in this setting and its interactions with acquired risk factors such as oral contraceptives, also highlighting the risk of recurrent thrombosis in cerebral vein thrombosispatients.
Authors: Patrícia Canhão; José M Ferro; Arne G Lindgren; Marie-Germaine Bousser; Jan Stam; Fernando Barinagarrementeria Journal: Stroke Date: 2005-07-07 Impact factor: 7.914
Authors: I Gosk-Bierska; W Wysokinski; R D Brown; K Karnicki; D Grill; H Wiste; E Wysokinska; R D McBane Journal: Neurology Date: 2006-09-12 Impact factor: 9.910
Authors: F Dentali; D Poli; U Scoditti; M N D Di Minno; V De Stefano; V D Stefano; S Siragusa; M Kostal; G Palareti; M T Sartori; E Grandone; M C Vedovati; W Ageno; Anna Falanga; Teresa Lerede; Marina Bianchi; Sophie Testa; Dan Witt; Katie McCool; Eugenio Bucherini; Elisa Grifoni; Daniela Coalizzo; Raffaella Benedetti; Marco Marietta; Maria Sessa; Clara Guaschino; Giovanni di Minno; Antonella Tufano; Sofia Barbar; Alessandra Malato; Mario Pini; Paola Castellini; Stefano Barco; Marisa Barone; Maurizio Paciaroni; Andrea Alberti; Giancarlo Agnelli; Matteo Giorgi Pierfranceschi; Petr Dulicek; Mauro Silingardi; Landini Federica; Angelo Ghirarduzzi; Eros Tiraferri; Vincenzo di Lazzaro; Elena Rossi; Angela Ciminello; Samantha Pasca; Giovanni Barillari; Emanuele Rezoagli; Matteo Galli; Alessandro Squizzato; Alberto Tosetto Journal: J Thromb Haemost Date: 2012-07 Impact factor: 5.824
Authors: Gie Ken-Dror; Ioana Cotlarciuc; Ida Martinelli; Elvira Grandone; Sini Hiltunen; Erik Lindgren; Maurizio Margaglione; Veronique Le Cam Duchez; Aude Bagan Triquenot; Marialuisa Zedde; Michelangelo Mancuso; Ynte M Ruigrok; Thomas Marjot; Brad Worrall; Jennifer J Majersik; Tiina M Metso; Jukka Putaala; Elena Haapaniemi; Susanna M Zuurbier; Matthijs C Brouwer; Serena M Passamonti; Maria Abbattista; Paolo Bucciarelli; Braxton D Mitchell; Steven J Kittner; Robin Lemmens; Christina Jern; Emanuela Pappalardo; Paolo Costa; Marina Colombi; Diana Aguiar de Sousa; Sofia Rodrigues; Patrícia Canhão; Aleksander Tkach; Rosa Santacroce; Giovanni Favuzzi; Antonio Arauz; Donatella Colaizzo; Kostas Spengos; Amanda Hodge; Reina Ditta; Alessandro Pezzini; Stephanie Debette; Jonathan M Coutinho; Vincent Thijs; Katarina Jood; Guillaume Pare; Turgut Tatlisumak; José M Ferro; Pankaj Sharma Journal: Ann Neurol Date: 2021-09-29 Impact factor: 10.422